

# Contents

---

## SECTION 1: MATERNAL FETAL MEDICINE

---

<b>1. Newer Markers in Prediction of Pre-Eclampsia</b>	<b>1</b>
<i>Monika Gupta, Reema Kumar</i>	
• Screening of Pre-Eclampsia	1
• Basis of Markers in Pre-Eclampsia Screening	2
• Placental Growth Factor	2
• Soluble Fms-Like Tyrosine Kinase-1	3
• Soluble Endoglin	3
<b>2. Noninvasive Prenatal Diagnosis in a Nutshell</b>	<b>6</b>
<i>Seema Thakur</i>	
• Cell-Free Fetal DNA	6
• Indications of Noninvasive Prenatal Testing	7
• Recommendations of Professional Societies	7
• Interpretation of NIPT Results	8
• Screening Performance	10
<b>3. Intrauterine Growth Restriction: Evidence-Based Management</b>	<b>12</b>
<i>Monika Gupta, Reema Kumar</i>	
• Fetal Doppler in Fetal Growth Restriction	12
• Stage-Based Management of Fetal Growth Restriction	13
• Stage-Based Classification and Management of FGR	14
• Decision Algorithm for the Management of FGR	16
<b>4. Management Algorithm of HBsAg-Positive Pregnant Women – Prevention of Mother-to-Child Transmission of Hepatitis B</b>	<b>18</b>
<i>Sharda Patra</i>	
<b>5. Recurrent Pregnancy Loss: Genetic Counseling</b>	<b>20</b>
<i>Mala Arora</i>	
• Recurrent Pregnancy Loss	20
• Genetic Counselling in RPL	23
• Genetic Tests	23
• Live Born Consequences of RPL	27

## SECTION 2: PRETERM LABOR

6. **Intrauterine Infection in Preterm Labor and Premature Rupture of Membranes** 29  
*Manju Puri, Sharda Patra*
  - *Infections Associated with Preterm Labor and PPROM* 29
  - *Pathogenesis* 31
  - *Diagnosis of Intra Amniotic Infection* 32
  - *Role of Antibiotics in Preterm Labor and PPROM* 33
7. **Ultrasound Evaluation of Fetal Lung Maturity: An Update** 37  
*Ashok Khurana*
  - *Evaluation of Fetal Lung Maturity* 38
8. **Managing Preterm Labor: What Does Evidence Say?** 41  
*Seema Hakim*
  - *Prevention of Preterm Births* 42
  - *ACOG (2012) Recommendations* 42
  - *National Institute for Health and Care Excellence (Nice) Guidelines (2015) Recommendations<sup>11</sup>* 43
  - *Treatment of Preterm Labor* 43
9. **Cervical Cerclage for Preventing Preterm Labor: An Overview** 51  
*Monika Gupta, Reema Kumar*
  - *Transabdominal Cerclage* 51
  - *Transcervical Emergency Cerclage* 53
  - *Evidence Review* 54

## SECTION 3: CRITICAL CARE IN OBSTETRICS

10. **Need for High Dependency Unit (HDU)/Intensive Care Unit (ICU)** 56  
*Alpesh Gandhi*
  - *What is the Need?* 56
  - *Obstetric ICU/HDU* 57
  - *Admission Indications* 58
11. **Standardization of Labor Rooms at Delivery Points - A Critical Intervention for Improving Maternal and Fetal Outcomes** 61  
*Pratima Mittal*
  - *Standardization of Labor Rooms* 61
12. **Impact of Physiological Changes in Management of Critically Ill Obstetric Patients** 68  
*Jyotsna Suri*
  - *Cardiovascular System* 68
  - *Hematological System* 71

• Respiratory System	72
• Urinary System	73
• Gastrointestinal Tract	73
• Thyroid Gland	74
<b>13. Antimicrobials in Sepsis: An Update</b>	<b>76</b>
<i>Rekha Bharti</i>	
• International Guidelines for Management of Sepsis and Septic Shock (2016)	76
• Timing of Antimicrobials Administration	78
• Antimicrobial Protocols for Obstetric Infections	78
<b>14. Blood Transfusion: What and When and How?</b>	<b>81</b>
<i>Monika Gupta, Divya Pandey</i>	
• Indications of Blood Transfusion in Obstetrics Patients	81
• Blood Transfusion in Special Conditions	82
• Various Blood Products Transfused in Clinical Practice	83
• Massive Blood Transfusion	84
• Important Aspects	85
• Transfusion Reactions	85
<b>15. ABG Analysis - What an Obstetrician Should Know?</b>	<b>88</b>
<i>JC Suri</i>	
• Acid-Base Terminology	88
• Acid-Base Physiology	88
• Simple Acid-Base Disorders	89
• Approach to a Patient with Acid-Base Disorder	91
• Few Case Illustrations	92

## SECTION 4: DECODING STILLBIRTH

<b>16. Overview of Still Birth: Global Scenario</b>	<b>94</b>
<i>Harsha Gaikwad</i>	
• What we Know About Stillbirth—A Devastating Tragedy	94
• Classification of Stillbirth for Assigning Cause of Death	94
• What to do When a Stillbirth Takes Place	96
• Management	97
• Way Forward	97
<b>17. Maternal Evaluation in Case of Stillbirth</b>	<b>98</b>
<i>Neelam Agarwal</i>	
• Definition of Stillbirth	98
• Prevalence	98
• Causes of Stillbirth	99
• Risk Factors for Stillbirth	99
• Maternal Evaluation	99

<b>18. Fetal Evaluation in Case of Stillbirth</b>	<b>105</b>
<i>Manisha Kumar</i>	
• <i>Why should Fetal Autopsy be Done?</i>	105
• <i>Components of Fetal Autopsy</i>	105
• <i>Noninvasive Autopsy</i>	110
<b>19. Genetic Evaluation for Single Gene Defects in Stillbirth</b>	<b>113</b>
<i>Chanchal Singh</i>	
• <i>Inheritance Patterns</i>	113
• <i>Genetic Evaluation in Unexplained Stillbirth</i>	115
• <i>Evaluation for Single Gene Disorders</i>	116
• <i>Prenatal Diagnosis of Single Gene Disorders</i>	116
• <i>Preimplantation Genetic Diagnosis</i>	117
<b>20. Unexplained Stillbirth</b>	<b>120</b>
<i>Chinmayee Ratha</i>	
• <i>Case Scenario</i>	121
• <i>Evaluating the Risk Factors</i>	121
• <i>Plan for Future</i>	122

## SECTION 5: ADOLESCENT HEALTH

<b>21. Adolescent Health Programs in India: Current Update</b>	<b>124</b>
<i>Monika Gupta</i>	
• <i>Kishori Shakti Yojna (KSY)</i>	124
• <i>Nutrition Program for Adolescent Girls (NPAG)</i>	125
• <i>Rajiv Gandhi Scheme For Empowerment of Adolescent Girls (RGSEAG): SABLA</i>	126
• <i>Balika Samridhi Yojana</i>	126
• <i>Adolescent Reproductive and Sexual Health (ARSH)</i>	127
• <i>Mahila Samakhyia Program</i>	128
• <i>Adolescence Education Program (AEP)</i>	128
• <i>Yuva-Youth Unite for Victory on AIDS</i>	129
• <i>Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCH+A)</i>	129
• <i>Rashtriya Kishor Swasthaya Karyakaram (Rksk)</i>	130
• <i>Protection of Children from Sexual Offences (POCSO) Act 2012</i>	130
<b>22. Abnormal Uterine Bleeding in Adolescents</b>	<b>132</b>
<i>Sampath Kumari</i>	
• <i>Case Scenario 1</i>	132
• <i>Physiology of Menstruation</i>	133
• <i>Causes of AUB</i>	133
• <i>Case Scenario 2</i>	134
• <i>Case Scenario 3</i>	135
• <i>Laboratory Evaluation</i>	135
• <i>Case Scenario 4</i>	136
• <i>Management</i>	137

<b>23. Teenage Pregnancy</b>	<b>140</b>
<i>Roza Olyai</i>	
• <i>Worldwide Picture</i>	140
• <i>Factors Contributing to Teenage Pregnancy</i>	141
• <i>Impact of Teenage Pregnancy</i>	142
• <i>Risk Associated with Teenage Pregnancy</i>	142
• <i>Management</i>	144
• <i>Preventing Teenage Pregnancy</i>	145
<b>24. Nutrition in Adolescents</b>	<b>147</b>
<i>Ragini Agrawal</i>	
• <i>Adolescence: Nutritionally Critical Period</i>	147
• <i>Energy and Protein Requirements</i>	148
• <i>Mineral and Micronutrient Requirements</i>	148
• <i>Other Minerals</i>	149
• <i>Vitamin Requirements</i>	150
• <i>Recommendations</i>	150
<b>25. Adolescent Counselling: An Insight</b>	<b>152</b>
<i>Pratima Mittal, Monika Gupta</i>	
• <i>What does Counseling Mean?</i>	152
• <i>Role of Gynecologists</i>	153
• <i>Providers Attributes</i>	153
• <i>Counseling Approach</i>	153
• <i>Components of Adolescent Counseling</i>	155
• <i>Challenges in Adolescent Counseling</i>	155
• <i>Time Requirement for Counseling</i>	156
• <i>Adolescent Friendly Health Services</i>	156
<b>26. Cosmetic Concerns in Adolescents</b>	<b>158</b>
<i>Neeta Dhabhai</i>	
• <i>Global Scenario</i>	158
• <i>Psychosocial Determinants of Body Image</i>	159
• <i>Consequences</i>	159
• <i>Screening/Assessment</i>	159
• <i>Breast Augmentation</i>	160
• <i>Rhinoplasty</i>	160
• <i>Otoplasty</i>	161
• <i>Dermabrasion and Microdermabrasion</i>	161
• <i>Laser Hair Removal</i>	161
• <i>Role of Care Provider</i>	161
<b>27. Adolescent Friendly Health Services: What is Needed?</b>	<b>163</b>
<i>Parag Biniwale, Monika Gupta</i>	
• <i>Investing in Adolescent Health</i>	163
• <i>WHO-defined Dimensions of Quality Health Services to Adolescents</i>	165
• <i>Adolescent Friendly Health Services (AFHS) in India</i>	165

- Facility-based Staff 166
- Services Provided by the Staff 166
- Monitoring of Program 167

## SECTION 6: INFERTILITY

- |   |            |
|---|------------|
| <b>28. Polycystic Ovarian Syndrome and Infertility</b>  | <b>168</b> |
| <i>Sonia Malik</i>  |            |
| <ul style="list-style-type: none"> <li>• Diagnosis 168</li> <li>• PCOS Phenotypes 169</li> <li>• Biochemical Tests and Classification Systems 170</li> <li>• Etiology 171</li> <li>• Controversies Regarding Treatment 172</li> </ul>   |            |
| <b>29. Tubal Patency Tests: Which One to Do?</b>  | <b>178</b> |
| <i>Divya Pandey, Monika Gupta</i>   |            |
| <ul style="list-style-type: none"> <li>• Hysterosalpingography 178</li> <li>• Laparoscopy with Chromopertubation 179</li> <li>• Hysterosalpingo-Contrast-Sonography 180</li> <li>• What does the Evidence Say? 181</li> </ul>   |            |
| <b>30. Hysteroscopy in Infertility: Myths and Facts</b>   | <b>184</b> |
| <i>Fessy Louis T</i>  |            |
| <ul style="list-style-type: none"> <li>• Basic Steps 184</li> <li>• Abnormalities in the Uterine Cavity and Treatment 186</li> <li>• Asherman's Syndrome and ART 191</li> <li>• Hysteroscopy in in-vitro Fertilization 192</li> <li>• Hystereoscopy after Repeated IVF Failures 192</li> <li>• Complications 192</li> </ul> |            |
| <b>31. Coup D'oeil into the Embryo – PGD /PGS Controversies</b>   | <b>195</b> |
| <i>Bharati Dhorepatil</i>   |            |
| <ul style="list-style-type: none"> <li>• Recommendations of PGS/PGD-Embryo Selection 195</li> <li>• Controversies of Antenatal Testing 196</li> <li>• Controversies Specific to Preimplantation Genetic Testing 196</li> </ul>  |            |
| <b>32. Fresh Embryo Transfer vs Freeze All–What is all the Fuss About?</b>  | <b>199</b> |
| <i>Pranay Ghosh</i>   |            |
| <ul style="list-style-type: none"> <li>• Effects of Controlled Ovarian Stimulation 200</li> <li>• Freeze-all Strategy: Strengths and Weaknesses 204</li> </ul>  |            |
| <b>33. Time-Lapse Monitoring: Busting Myths</b>   | <b>208</b> |
| <i>Keshav Malhotra</i>  |            |
| <ul style="list-style-type: none"> <li>• Limitations of Existing Models 209</li> <li>• Limitations of Time-Lapse Technology 211</li> </ul>  |            |

## SECTION 7: MYOMA

- 34. Minimally Invasive Management of Myomas: A Comprehensive Review** **216**  
*Urvashi Prasad, Neema Sharma, Ramandeep Kaur*
- *Laparoscopic Myomectomy* 216
  - *Indications* 217
  - *Contraindications to Laparoscopic Myomectomy* 217
  - *Preoperative Preparation* 217
  - *Intraoperative Requirements* 220
  - *Postoperative Monitoring* 228
  - *Hysteroscopic Myomectomy* 228
  - *Indications for Hysteroscopic Myomectomy* 228
  - *Preoperative Assessment* 228
  - *Preoperative Preparation* 230
  - *Myomectomy Techniques* 230
  - *Complications* 231
- 35. Myoma and Subfertility** **235**  
*Reeta Mahey*
- *Impact of Fibroids on Fertility* 235
  - *Effect of Myomectomy on Reproductive Potential* 236
  - *Practice Points for Managing Fibroids in Infertility* 237
- 36. Newer Drugs in Medical Management of Uterine Myoma** **240**  
*Bindiya Gupta*
- *Medical Management* 241
  - *Gonadotrophin-Releasing Hormone Analogs* 241
  - *Gonadotrophin-Releasing Hormone Antagonists* 241
  - *Aromatase Inhibitors* 241
  - *Selective Estrogen Receptor Modulators (Serms)* 244
  - *Progesterone Antagonists* 244
  - *Selective Progestrone Receptor Modulators* 244
  - *Other Hormonal Agents* 245
  - *Future Drugs* 245
- 37. Management of Uterine Myomas: Evidence-Based Algorithm** **248**  
*Puneet Kochhar*
- *Points to Remember* 248

## SECTION 8: UROGYNAECOLOGY

- 38. Approach to a Female with Urinary Incontinence** **252**  
*Monika Gupta*
- *Types of Incontinence* 252
  - *Diagnosis and Assessment of Severity* 253

- *Bladder Diary* 253
  - *Physical Examination* 254
  - *Questionnaires* 254
  - *Laboratory Evaluation* 254
  - *Management* 255
  - *Nonpharmacologic Therapy* 255
  - *Pharmacologic Therapy* 258
  - *Minimally Invasive Procedures* 259
  - *Surgery* 259
- 39. Overactive Bladder: An Update** 263  
*Amita Jain*
- *Evaluation of OAB* 263
  - *Physical Examination* 265
  - *Investigations* 265
  - *Treatment* 266
  - *First-Line Treatments: Behavioral Therapies* 266
  - *Second-Line Treatments* 266
  - *Third-Line Treatment* 267
  - *Additional Treatments* 268
- 40. Botulinum Toxin in Idiopathic Overactive Bladder: State of the Art** 270  
*Pawan Vasudeva, Niraj Kumar*
- *Available Preparations* 270
  - *Procedure and Dosage* 271
  - *What does Evidence Say?* 271
  - *Complications* 272
- 41. Interstitial Cystitis/Bladder Pain Syndrome: Clinical Aspects** 276  
*Rajesh Taneja*
- *Interstitial Cystitis/Bladder Pain Syndrome* 276
  - *Gibbs Definition of IC/BPS* 277
  - *Clinical Approach to a Patient with Suspected IC/BPS* 277
  - *History* 277
  - *Examination* 278
  - *Investigations* 279
  - *Management of IC/BPS Patient Education* 280
  - *Oral Nonspecific Medication* 280
  - *Oral Specific Medication* 281
  - *Intravesical Treatments* 281
  - *Dietary Modification* 282
  - *Pain Management* 282
- 42. Management of Prolapse: Evolving Trends** 285  
*Mangesh Narwadkar*
- *Background of Prolapse Surgeries* 285
  - *Concept of Newer Surgeries* 286



- *Tension-Free Vaginal Mesh (TVM)* 286
- *Mesh Use in Prolapse Surgery* 287
- *Surgical Robotics* 290

#### 43. Role of Minimally Invasive Surgery in Urogynecology 292

*Karishma Thariani, JB Sharma*

- *Laparoscopic Sacrocolpopexy for Vaginal Vault Prolapse* 292
- *Laparoscopic Uterine Preservation Surgeries for Uterine Prolapse* 293
- *Laparoscopy in Stress Urinary Incontinence* 294
- *Laparoscopic Anterior Wall Prolapse Repair* 294
- *Laparoscopic Posterior Wall Prolapse Repair* 296
- *Tension-Free Vaginal Tape (TVT)* 296
- *Transobturator Tape (TOT)* 297

#### 44. Incontinence Devices: Bridging the Breach in the Dam 299

*Achla Batra*

- *Incontinence Devices* 299
- *Intravaginal Supportive Devices (Pessaries)* 300
- *Other Reusable Vaginal Incontinence Devices* 302
- *Occlusive Devices* 305

### SECTION 9: PREVENTIVE ONCOLOGY

#### 45. Gonadal Health and Screening 307

*Neerja Bhatla, Monika Gupta*

- *Malignant Ovarian Neoplasms: Ovarian Cancer* 307
- *Why is Screening for Ovarian Cancer Necessary?* 308
- *Challenges in Developing Strategies for Ovarian Cancer Screening* 308
- *Screening for Ovarian Cancer in General Population* 308
- *Screening in High-Risk Women* 309
- *Serum Ca-125 as Tumor Marker and Risk of Ovarian Cancer Algorithm* 309
- *Major Ovarian Cancer Screening Trials* 310
- *Other Biomarkers* 310
- *Current Status of Ovarian Cancer Screening* 311

#### 46. Cervical Cancer Screening: In a Nutshell 315

*Nisha Singh*

- *Cervical Cancer Screening Tools* 316
- *Guidelines for Cervical Cancer Screening (ACOG, ACS and ASCCP)* 322
- *Who Screen and Treat Recommendations* 323
- *National Cancer Control Program of India* 323

#### 47. Colposcopic Visualization of Normal and Abnormal Cervix 325

*Dipanwita Banerjee, Ranajit Mandal*

- *Indications for Colposcopy* 325
- *Colposcopic Features of Normal Cervix* 326

**48. Endometrial Hyperplasia Management: Current Guidelines** 331

*Shalini Rajaram*

- *Risk Factors* 331
- *Clinical Presentation* 332
- *Management of Endometrial Hyperplasia without Atypia* 332
- *Management of Endometrial Hyperplasia with Atypia* 334
- *Hormone Replacement Therapy and Endometrial Hyperplasia* 334
- *Tamoxifen with Endometrial Hyperplasia* 335

*Index* 337